
Jamieson Wellness Inc. Reports First Quarter 2025 Results
TORONTO--(BUSINESS WIRE)--Jamieson Wellness Inc. ('Jamieson Wellness' or the 'Company') (TSX: JWEL) today reported its first quarter results for the period ended March 31, 2025. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See 'Non-IFRS and Other Financial Measures' below.
'Our team delivered solid results in Q1 that continued to demonstrate the power of our strategy in action,' said Mike Pilato, President and CEO of Jamieson Wellness. 'Consolidated revenue growth in the quarter was 14%, and branded revenue growth of 13.9% exceeded our expectations. We also grew Adjusted EBITDA ahead of revenue, reflecting both sustained global demand for our products and our team's precise execution in meeting that opportunity.
"Our China business grew over 50% in Q1 as we capitalized on our strategic investments and tailored approach to this key region. In the U.S, we are on track to meet our growth expectations as we are actively expanding the youtheory brand with our new e-commerce partner. Our strategic initiatives in Canada and International markets reflected both category strength and our continued ability to outpace market growth.
"2025 is off to a great start. We're executing on our innovation roadmap, expanding channel reach, and enhancing operational efficiency to maintain this momentum. This focused strategy will continue to drive revenue, EBITDA, and cash flow growth in the coming year. We're grateful for our team's unwavering dedication and the loyalty of our customers and consumers as we continue to deliver innovative natural health solutions and build on our foundation of profitable growth."
First Quarter Highlights
Strong consumer consumption in Canada led by continued growth in club and e-commerce channels
Revenue growth in China exceeded expectations, driven by strengthening brand awareness, focus on social commerce, retail, and cross-border strategies
Elevated consumer consumption of the youtheory brand across all channels, impacted by timing of innovations in the same quarter prior year
Immunity and women's health focused campaigns drove demand in the Middle East and Asia
Published second annual sustainability impact report, detailing progress towards the Company's 2030 and 2050 sustainability goals
First Quarter Financial Results Consolidated Summary
All comparisons are with the first quarter of 2024
Consolidated revenue increased 14.0% to $146.0 million, driven by 13.9% growth in Jamieson Brands and 14.9% growth in Strategic Partners
Gross profit increased by $12.4 million to $55.2 million; normalized gross profit increased by $10.4 million largely driven by higher revenues and increased margins
Gross profit margin 3 increased by 440 basis points; normalized gross profit margin increased 270 basis points due to volume driven efficiencies and favourable channel mix
EBITDA 1 increased by $0.6 million to $7.8 million, mainly driven by higher revenues and gross profit; Adjusted EBITDA 1 increased by $3.0 million or 18.4% to $19.1 million, reflecting the impact of higher sales volumes and gross profit margins, partially offset by investments in SG&A
Net loss was $2.5 million; Adjusted net earnings 1 was $5.9 million, or $2.0 million higher, reflecting higher normalized earnings from operations
Diluted earnings per share was ($0.06); Adjusted diluted earnings per share 2 was $0.14
Summary of Segment Results
All comparisons are with the first quarter of 2024
Jamieson Brands
Revenue increased 13.9% or $16.0 million to $131.4 million
Canada revenue increased by 14.3% to $69.5 million, driven by continued strong consumer consumption and pricing while lapping lower shipments prior year due to the labour disruption
China revenue increased 52.1% to $28.5 million, driven by strengthening of brand awareness and growth in social e-commerce that continues to outpace the market
youtheory revenue declined by 13.0% to $26.5 million as expected. Strong consumption driving shipment growth of 16.5% in traditional channels in the quarter was offset by the impact of lapping innovation pipefill in Q1 2024. Q1 2025 revenue growth increased by 19.3% vs Q1 2023.
International revenue increased by 28.8% to $6.9 million, driven by growth in key markets while lapping lower shipments prior year due to the labour disruption
Gross profit increased by $12.7 million to $53.8 million; normalized gross profit increased by $10.4 million mainly due to higher revenues and increased margins
Gross profit margin 3 increased by 520 basis points to 40.9%; normalized gross profit margin increased by 320 basis points to 41.7%, mainly due to volume driven efficiencies and favourable channel mix
Adjusted EBITDA 1 increased by $3.1 million to $18.3 million, driven by higher gross profit partially offset by increased investments in SG&A to support growth and brand awareness in China; Adjusted EBITDA margin 2 was 13.9%, an increase of 80 basis points mainly due to higher normalized gross profit
Strategic Partners
Revenue increased 14.9% or $1.9 million to $14.6 million, driven by shipments of new customer contracts awarded in the fourth quarter of the prior year and timing of customer orders
Gross profit was $1.4 million, a decrease of $0.2 million; gross profit margin 3 was 9.8%, a decrease of 320 basis points; normalized gross profit margin decreased by 160 basis points to 11.4% driven mainly by customer mix
Adjusted EBITDA 1 was $0.8 million, a decrease of $0.2 million; Adjusted EBITDA margin 2 was 5.4%, a decrease of 230 basis points
Balance Sheet and Cash Flow from Operations
All comparisons are with the first quarter of 2024
As at March 31, 2025, the Company had approximately $246.1 million in cash and available revolving and swingline facilities and net debt 1 of $253.9 million
The Company generated $31.6 million in cash from operations compared to $7.3 million used in Q1 2024
Cash from operating activities before working capital considerations of $4.7 million was consistent with prior year
Cash generated from working capital increased by $38.8 million driven by lower accounts receivable due to the timing of customer collections
During the period ended March 31, 2025, the Company purchased for cancellation 348,160 Common Shares under its NCIB program for an aggregate consideration of $10.0 million
1 This is a non-IFRS financial measure. See the 'Non-IFRS and Other Financial Measures' section of this press release for more information on each non-IFRS financial measure.
2 This is a non-IFRS ratio. See the 'Non-IFRS and Other Financial Measures' section of this press release for more information on each non-IFRS ratio.
3 This is a supplementary financial measure. See the 'Non-IFRS and Other Financial Measures' section of this press release for more information on each supplementary financial measure.
Expand
Maintaining Fiscal 2025 Outlook
The Company is maintaining its outlook for the 2025 fiscal year and continues to anticipate the following:
Revenue to range between $800.0 to $840.0 million (+9.0% to +14.5% growth)
Adjusted EBITDA to range from $157.0 to $163.0 million (+11.0% to +15.5% growth)
Adjusted diluted earnings per share to range from $1.82 to $1.93 (+13.0% to +20.0% growth)
Based on the currently announced tariff framework, which the Company recognizes is constantly evolving, no material impact is expected in 2025. For additional details on the Company's fiscal 2025 outlook, including guidance for the second quarter of 2025, refer to the 'Outlook' section in the management's discussion and analysis of financial condition and results of operations ('MD&A') for the three months ended March 31, 2025.
Declaration of First Quarter Dividend
The board of directors of the Company declared a cash dividend for the first quarter of 2025:
$0.21 per common share, or approximately $8.8 million in the aggregate
Paid on June 13, 2025 to all common shareholders of record at the close of business on May 30, 2025
The Company has designated this dividend as an 'eligible dividend' for the purposes of the Income Tax Act (Canada)
Consolidated Financial Statements and Management's Discussion and Analysis
The Company's unaudited condensed consolidated interim financial statements and accompanying notes as at and for the three months ended March 31, 2025 and related MD&A are available under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com.
Conference Call
Management will host a conference call to discuss the Company's first quarter 2025 results at 5:00 p.m. ET today, May 8, 2025. To access:
By phone: 1-844-763-8274 from Canada and the U.S. or 1-647-484-8814 from international locations
Online: https://investors.jamiesonwellness.com or https://www.gowebcasting.com/14031
About Jamieson Wellness
Jamieson Wellness is dedicated to Inspiring Better Lives Every Day with its portfolio of innovative natural health brands. Established in 1922, the Jamieson brand is Canada's #1 vitamins, minerals and supplements ('VMS') brand. The Company's youtheory brand, acquired in 2022, is an established and growing lifestyle brand in the U.S. Combined, these global brands are available in more than 50 countries worldwide. The Company also offers a variety of innovative VMS products as well as sports nutrition products to consumers in Canada with its Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit jamiesonwellness.com.
Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.
Forward-Looking Information
This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2024 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as 'expect', 'anticipate', 'intend', 'may', 'will', 'estimate' and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's Annual Information Form dated March 31, 2025 and under the 'Risk Factors' section in the MD&A filed today, May 8, 2025. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.
The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See 'Forward-looking Information' and 'Risk Factors' within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.
Jamieson Wellness Inc.
Consolidated Statements of Financial Position
In thousands of Canadian dollars
December 31,
2024
Assets
Current assets
Cash
41,113
44,787
Accounts receivable
128,113
228,031
Inventories
177,947
154,658
Derivatives
1,441
2,661
Prepaid expenses and other current assets
8,757
6,803
Income taxes recoverable
4,037
-
361,408
436,940
Non-current assets
Property, plant and equipment
102,294
103,591
Goodwill
287,454
287,503
Intangible assets
375,684
377,214
Deferred income tax
3,855
3,545
Total assets
1,130,695
1,208,793
Liabilities
Current liabilities
Accounts payable and accrued liabilities
97,284
137,653
Income taxes payable
990
4,373
Derivatives
2,688
2,982
Current portion of other long-term liabilities
27,740
27,673
128,702
172,681
Long-term liabilities
Long-term debt
295,000
308,285
Post-retirement benefits
1,238
1,209
Deferred income tax
62,601
64,467
Redeemable preferred shares
100,410
98,138
Other long-term liabilities
14,334
15,633
Total liabilities
602,285
660,413
Equity
Share capital
325,426
326,219
Warrants
14,705
14,705
Contributed surplus
24,029
23,835
Retained earnings
80,521
99,109
Accumulated other comprehensive income
40,576
41,313
Total shareholders' equity
485,257
505,181
Non-controlling interests
43,153
43,199
Total equity
528,410
548,380
Total liabilities and equity
1,130,695
1,208,793
Expand
Non-IFRS and Other Financial Measures
This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. The Company uses the following non-IFRS financial measures: 'EBITDA', 'Adjusted EBITDA' and 'Adjusted net earnings', the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, 'normalized gross profit', 'normalized SG&A', 'normalized earnings from operations', 'cash from operating activities before working capital considerations' and 'net debt', the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: 'Adjusted EBITDA margin', 'Adjusted diluted earnings per share', 'normalized gross profit margin', 'normalized operating margin', and the following supplementary financial measures: 'gross profit margin' and 'operating margin' to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non-IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the 'How we Assess the Performance of our Business' section of the MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company's financial statements to which the measure relates.
The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as gross profit to normalized gross profit, SG&A to normalized SG&A, earnings from operations to normalized earnings from operations and net debt, each of which are non-IFRS financial measures (see the 'Non-IFRS and Other Financial Measures' of this press release for further information on each non-IFRS financial measure) for the three months ended March 31, 2025.
Reconciliation of Non-IFRS Financial Measures
In thousands of Canadian dollars
Three months ended
March 31
2025
2024
Net loss:
(2,514
)
(3,719
)
Add:
Recovery of income taxes
(1,624
)
(1,124
)
Interest expense and other financing costs
4,908
4,873
Accretion on preferred shares
2,272
2,219
Depreciation of property, plant, and equipment
3,255
3,516
Amortization of intangible assets
1,500
1,384
Earnings before interest, taxes, depreciation, and amortization (EBITDA)
7,797
7,149
Share-based compensation (3)
2,087
1,749
Foreign exchange loss/(gain)
504
(771
)
Labour relations costs (1)
-
4,693
IT system implementation (2)
5,535
2,980
Donations (4)
3,118
-
Legal and other
25
297
Adjusted EBITDA
19,066
16,097
Recovery of income taxes
1,624
1,124
Interest expense and other financing costs
(4,908
)
(4,873
)
Depreciation of property, plant, and equipment
(3,255
)
(3,516
)
Amortization of intangible assets
(1,500
)
(1,384
)
Share-based compensation (3)
(1,965
)
(1,627
)
Tax deduction from vesting of certain share-based awards
(689
)
-
Tax effect of normalization adjustments
(2,425
)
(1,906
)
Adjusted net earnings
5,948
3,915
Three months ended
March 31
2025
2024
Gross profit
55,220
42,785
Labour relations costs (1)
-
3,253
IT system implementation (2)
1,249
-
Normalized gross profit
56,469
46,038
Normalized gross profit margin
38.7
%
36.0
%
Selling, general and administrative expenses
49,587
39,558
Donations (4)
(3,118
)
-
IT system implementation (2)
(4,286
)
(2,980
)
Labour relations costs (1)
-
(1,440
)
Legal and other
(25
)
(297
)
Normalized selling, general and administrative expenses
42,158
34,841
Earnings from operations
3,546
1,478
IT system implementation (2)
5,535
2,980
Labour relations costs (1)
-
4,693
Donations (4)
3,118
-
Legal and other
25
297
Normalized earnings from operations
12,224
9,448
Normalized operating margin
8.4
%
7.4
%
Expand
(1)
Prior year expenses are comprised of third party legal, security fees and unavoidable facility expenditures. All expenses are directly related to the facility closure and collective bargaining process with unionized employees at a manufacturing and warehousing facility in Windsor, Canada.
(2)
Mainly pertains to development and post implementation start-up costs associated with our IT system implementation to augment our system infrastructure. Unlike other system improvement projects with costs capitalized, due to its cloud-based nature, these system implementation costs are expensed accordingly.
(3)
Our share-based compensation expense pertains to our long-term incentive plan, with stock options, performance-based share units, time-based restricted share units, and deferred share units expenses, along with associated payroll taxes.
(4)
Include cash and in-kind donations to support communities adjacent to our Irvine, California facility impacted by the wildfires.
Expand
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
30 minutes ago
- Business Wire
Spanish Mountain Gold Announces Grant of Stock Options
VANCOUVER, British Columbia--(BUSINESS WIRE)--Spanish Mountain Gold Ltd. (the " Company" or " Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) announces that it has granted 2,860,500 stock options to officers and directors of the Company and 221,500 stock options to employees and consultants pursuant to the terms of the Company's stock option plan. Each option entitles the holder to acquire one Common Share at an exercise price of $0.175 per Common Share for ten years. About Spanish Mountain Gold Ltd. Spanish Mountain Gold Ltd. is focused on advancing its 100%-owned Spanish Mountain Gold Project (Project) towards construction of the next gold mine in the Cariboo Gold Corridor, British Columbia. The Company expects to release at the end of Q2, 2025, the results for the Project's newly de-risked and optimized Preliminary Economic Assessment (PEA) with an updated Mineral Resource Estimate (MRE). Upon receipt of the new PEA and updated MRE, the company will decide the next steps to advance the Project to position the company to make a construction decision in or before 2027. We are striving to be a leader in community and Indigenous relations by leveraging technology and innovation to build the 'greenest' gold mine in Canada. The Relentless Pursuit for Better Gold means seeking new ways to achieve optimal financial outcomes that are safer, minimize environmental impact and create meaningful sustainability for communities. Details on the Company are available on and on the Company's website: On Behalf of the Board, 'Peter Mah' President, Chief Executive Officer and Director Spanish Mountain Gold Ltd. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. FORWARD-LOOKING INFORMATION: Certain of the statements and information in this press release constitute "forward-looking information". Any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "anticipates", "believes", "plans", "estimates", "intends", "targets", "goals", "forecasts", "objectives", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be considered forward-looking information. The Company's forward-looking information is based on the assumptions, beliefs, expectations and opinions of management as of the date of this press release and include but are not limited to information with respect to, the potential to extend mineralization within the near-surface environment; the potential to expand resources and to find higher-grade mineralization at depth; the timing, size and budget of a winter drill program, and the results thereof; and the delivery of a maiden resource for the Phoenix Target, and the timing and results thereof. Other than as required by applicable securities laws, the Company does not assume any obligation to update forward-looking information if circumstances or management's assumptions, beliefs, expectations or opinions should change, or changes in any other events affecting such statements or information. For the reasons set forth above, investors should not place undue reliance on forward-looking information.


Hamilton Spectator
32 minutes ago
- Hamilton Spectator
Scotiabank ramps up return-to-office mandate to four days a week
Scotiabank is changing its return-to-office policy to require some employees to work in-person four days a week. In an internal memo shared last week, Scotiabank told staff the new mandate will apply starting in September. Teams that have limited office space will be expected to be present three or more days, with the goal of eventually having all employees based at the head office on Bay and King streets in four or more days each week, according to the memo seen by Bloomberg. And some employees won't be affected by the changes at all due to the nature of their work, with those on the global client-experience centre and Canadian banking collections teams seeing no change in their work arrangements. 'We know having our teams working together in-person has many benefits — greater collaboration, higher engagement, more career development opportunities, and a stronger culture and sense of belonging — and we are already seeing the positive impact this is having across the bank as we focus on executing on our strategy,' Scotiabank spokesperson Katie Raskina wrote in an emailed statement to the Star. 'We will continue to build on this impact as we bring our teams on-site more often, with the goal of reaching four days on-site across the bank over time.' One of the Big Six banks said it would tighten lending criteria for self-employed borrowers in Canada's Big Six banks, which have the largest presence in Toronto's financial district among other industries, have been leading the pack in the return-to-office movement . Since the COVID-19 pandemic, they started having workers back in the office as early as February 2022 — ahead of most companies. In May, it was reported that RBC has also asked its staff to work from the office four days a week, beginning in the fall. 'RBC is a relationship-driven bank, and in-person, human connection is core to our winning culture,' spokesperson Jeff Lanthier said in statement Monday. 'We have important commitments to our clients and bold goals for the future. We are confident that prioritizing working together in-person is a vital component in setting us up for continued, long-term success. Starting in September, we expect our employees around the world to be in the office, with flexibility to work remotely one day per week.' The Star contacted TD, CIBC, BMO and National Bank for their most recent return-to-office policies. National Bank spokesperson Alexandre Guay said each team has a different mandate depending on their needs — some employees work entirely in-person, while others follow a hybrid model. A CIBC spokesperson provided a similar statement. TD and BMO did not immediately respond to requests for comment. Last summer, the Star reported that Toronto Mayor Olivia Chow had met with several bank CEOs to discuss ways to get Torontonians back in the office at least four days a week, if not five, 'to make sure our financial district is vibrant.' She also said the banks had been calling on City Hall to 'set a good example and get all your workers back in.' With files from Bloomberg.
Yahoo
35 minutes ago
- Yahoo
MedX Announces Final Closing of Non-Brokered Private Placement
MISSISSAUGA, Ontario, June 09, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory "hold" period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ("Unit"). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant ("Warrant(s)"), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants ("Agent's Warrant(s)") (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant ("Agent's Share Purchase Warrant"), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. View source version on Contacts MedX Health Druhan, President, Dermatological (+1) 905-599-7852